- Home
- TLSI vs MOLN Comparison
TLSI vs MOLN Comparison
Compare TLSI & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- MOLN
- Stock Information
- Founded
- TLSI 2010
- MOLN 2004
- Country
- TLSI United States
- MOLN Switzerland
- Employees
- TLSI N/A
- MOLN N/A
- Industry
- TLSI Medical Specialities
- MOLN
- Sector
- TLSI Health Care
- MOLN
- Exchange
- TLSI Nasdaq
- MOLN Nasdaq
- Market Cap
- TLSI 158.0M
- MOLN 183.2M
- IPO Year
- TLSI N/A
- MOLN 2021
- Fundamental
- Price
- TLSI $5.77
- MOLN $4.68
- Analyst Decision
- TLSI Strong Buy
- MOLN
- Analyst Count
- TLSI 6
- MOLN 0
- Target Price
- TLSI $11.75
- MOLN N/A
- AVG Volume (30 Days)
- TLSI 40.4K
- MOLN 2.1K
- Earning Date
- TLSI 03-27-2025
- MOLN 03-13-2025
- Dividend Yield
- TLSI N/A
- MOLN N/A
- EPS Growth
- TLSI N/A
- MOLN N/A
- EPS
- TLSI N/A
- MOLN N/A
- Revenue
- TLSI $26,891,000.00
- MOLN $7,105,397.00
- Revenue This Year
- TLSI $61.29
- MOLN N/A
- Revenue Next Year
- TLSI $53.21
- MOLN N/A
- P/E Ratio
- TLSI N/A
- MOLN N/A
- Revenue Growth
- TLSI 67.90
- MOLN N/A
- 52 Week Low
- TLSI $3.50
- MOLN $3.32
- 52 Week High
- TLSI $10.42
- MOLN $12.70
- Technical
- Relative Strength Index (RSI)
- TLSI 68.94
- MOLN 35.14
- Support Level
- TLSI $5.40
- MOLN $4.78
- Resistance Level
- TLSI $5.82
- MOLN $4.96
- Average True Range (ATR)
- TLSI 0.24
- MOLN 0.08
- MACD
- TLSI 0.01
- MOLN -0.02
- Stochastic Oscillator
- TLSI 89.19
- MOLN 0.00
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.